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Genes for Cognitive Function: Developments on
the X
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North Adelaide, SA 5006, Australia; 2Department of Pediatrics, 3Department of Genetics, University of Adelaide,
Adelaide, Australia
Developments in human genome research enabled the first steps toward a molecular understanding of cognitive
function. That there are numerous genes on the X chromosome affecting intelligence at the lower end of the
cognitive range is no longer in doubt. Naturally occurring mutations have so far led to the identification of
seven genes accounting for a small proportion of familial nonspecific X-linked mental retardation. These new
data indicate that normal expression of many more X-linked and autosomal genes contribute to cognitive
function. The emerging knowledge implicating genes in intracellular signaling pathways provides the insight to
identify as candidates other X-linked and autosomal genes regulating the normal development of cognitive
function. Recent advances in unravelling the underlying molecular complexity have been spectacular but
represent only the beginning, and new technologies will need to be introduced to complete the picture.
The excess of males over females in the lower range of
IQ distribution has long been recognized (Penrose
1938). Recent large-scale longitudinal studies have
shown male excess at both ends of the distribution of
IQ scores. Moreover, these differences in variance be-
tween the two sexes (males show consistently higher
variance), although generally small, are stable over
time (Hedges and Nowell 1995). These observations are
consistent with the notion that at least a proportion of
cognitive function as measured by current tests is de-
termined by genes on the X chromosome. Although
the contribution of X-linked genes to increased IQ re-
mains an area of controversy (Lehrke 1972; Turner and
Partington 1991; Morton 1992; Turner 1996; Lubs et al.
1999), the fact that X-linked genes decrease IQ of males
is now well established, especially in families segregat-
ing X-linked mental retardation (XLMR).
Classification and Incidence of Mental Retardation
Mental retardation (MR) is defined as an IQ <70 and is
subdivided into ranges: borderline (~ 70), mild (50–69),
moderate (35–49), severe (20–34), and profound (<19).
Prevalence is 2%–3% of the population (for review, see
McLaren and Bryson 1987; Raynham et al. 1996; Crow
and Tolmie 1998). MR can be a component of a more
complex syndrome (e.g., Down syndrome, fragile X
syndrome, ATR-X syndrome), metabolic disorder (e.g.,
phenylketonuria), or neuromuscular disorder (e.g.,
Duchenne muscular dystrophy), or MR can be an ex-
clusive phenotype affecting only postnatal develop-
ment of cognitive function (nonspecific mental retar-
dation). Given the ease of expression of X-linked dis-
orders in hemizygous males, the X-chromosome has
become an obvious focus for beginning to map and
identify genes for syndromal and nonspecific MR. Syn-
dromal XLMR has been reviewed elsewhere (Lubs et al.
1999) and lies outside the scope of the present discus-
sion. The purpose of this review is to summarize cur-
rent knowledge of the molecular basis for nonspecific
mental retardation.
The first nonspecific XLMRs were mapped in 1988
(Arveiler et al. 1988; Suthers et al. 1988). Whereas syn-
dromal XLMR is named on the basis of the most dis-
tinctive clinical features or eponomously after the dys-
morphologists who described the associated distinctive
clinical features, an alternative nomenclature system
needed to be devised for nonspecific XLMR. Nonspe-
cific XLMR is defined as a nonprogressive genetically
heterogeneous condition that affects cognitive func-
tion in the absence of other distinctive dysmorphic,
metabolic, or neurologic features. The symbol MRX
was adopted for nonspecific X-linked MR, and sequen-
tial MRX numbers beginning with MRX1 (Suthers et al.
1988) were applied to families that satisfied MRX cri-
teria (Mulley et al. 1992).
The prevalence of all XLMRs is estimated to be
1.66/1000 males (Glass 1991; Turner et al. 1996). Esti-
mated incidence for MRX is 0.9–1.4/1000 males (Kerr
et al. 1991), a figure much higher than 0.22/1000 for
fragile X syndrome (Turner et al. 1996), the most com-
mon inherited familial MR. Although MRX is collec-
tively more common than fragile X syndrome, each
MRX is individually rare. The most common MRX re-
mains FRAXE MR, associated with amplification of
CCG within FMR2.
Currently, there are nearly 900 autosomal and X-
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linked entries with MR as an exclusive or inclusive phe-
notype in the OMIM database (http://www.ncbi.nlm.
nih.gov/Omim/). In ~ 75% of these, MR is a component
of a syndromal autosomal recessive or dominant phe-
notype. There is no known autosomal form of familial
nonspecific MR similar to MRX. A recent update on
XLMR (Lubs et al. 1999) reviewed 178 XLMR entries of
which 120 are syndromal (MRXS) and 58 are nonspe-
cific (MRX). Recent new ascertainments of MRX fami-
lies have increased the total to 75 at August 1999 (the
Ninth International Workshop on Fragile X Syndrome
and X-linked Mental Retardation, Strasbourg, France
1999). Although these families are slowly accumulat-
ing, families of sufficient size for gene localization and
assignment of an MRX symbol remain extremely rare,
emphasising the need for international collaboration.
Numerous smaller families are also undoubtedly X-
linked, including some containing affected females.
Affected females documented in the larger pedigrees
could be affected as a result of skewed X-chromosome
inactivation or partial dominance of the molecular de-
fect.
Resources and Approaches Leading to
Gene Identification
Since the publication of MRX1 (Suthers et al. 1988), a
significant resource of mapped MRX families has been
established, and additions remain ongoing. In the re-
cent past this was the point when the family study was
abandoned. The gene localization determined by link-
age in single families was too broad for positional clon-
ing; very few of the potential candidate genes had been
discovered, and there were no single obvious posi-
tional candidate genes to screen for mutations from
among the numerous genes that were known and ex-
pressed in brain. Moreover, refinement to gene local-
ization was not possible because the individual MRX
families could not be lumped together on the basis of
their “common” phenotype. The approach has
changed little in 5 years since Mandel (1994) lamented
that gene identification “will ultimately depend on
systematic screening of many probands for mutations
in many candidate genes.” What has changed drasti-
cally has been the availability of vast resources arising
from the Human Genome Project (Fig. 1).
An important focus of recent research has become
the identification of genes affected by X-chromosomal
rearrangements in patients with nonspecific MR. The
chromosomal rearrangements include balanced (at the
level of light microscopy) X; autosome translocations,
where the normal X is preferentially inactivated in af-
fected females, X-chromosome inversions in affected
males, and submicroscopic deletions in affected males.
X-chromosome genes structurally affected by break-
points or lost by deletion represent naturally occurring
human gene knockouts probably accounting for most
of the symptoms in the patients who have the chro-
mosomal aberrations. Moreover, these same genes be-
come instant candidates for familial MRX mapping by
linkage to the same locations. This approach represents
a lesson learned from the early positional cloning of
genes for other X-linked disorders such as Duchenne
muscular dystrophy. Precise determination of the
breakpoint at the level of the DNA sequence is facili-
tated by the availability of detailed physical maps (Na-
tional Center for Biotechnology Information, White-
head Institute at the Massachusetts Institute of Tech-
nology, Sanger Center, Washington University, Max
Planck Institute Berlin), clone reagents (idem; Roswell
Park) and FISH, partial gene sequences (ESTs, Unigene
clusters, THCs), rapidly growing genomic DNA se-
quence data in the public domain (http://
www.ncbi.nlm.nih.gov/genome/seq/), and overall glo-
balization (World Wide Web) of human genome re-
search. The human X chromosome is currently one of
the best characterized human chromosomes with
>35% of its estimated 150- to 160-Mb genomic se-
quence completed (>56.7 Mb as of 9/9/99; http://
www.ncbi.nlm.nih.gov/genome/seq/).
Two of the genes for familial MRX were identified
by positional cloning from within deletions. The first,
Figure 1 A flow diagram of the current approaches and re-
sources available for mapping and identification of MRX genes.
Currently two bags of resources are widely used, MRX families
(large, lod>2, and small lod<2) and individual patients with X
aberrations. Undoubtedly new technologies will play a major part
in speeding up the whole process on different levels: linkage
analysis (automated genotyping, SNP analysis); candidate gene
characterization (based on finished or a draft human genome
sequence) and expression analysis (ESTs, SAGE, cDNA microar-
rays); and high-throughput mutation detection technology (DNA
chips for known and new mutations, direct candidate gene mu-
tation screen). Application of forward genetics techniques (search
for interacting proteins, pathways) will add yet another dimen-
sion to the scheme. With this knowledge, resources, and tech-
nologies, the identification of autosomal genes involved in as-
pects of cognitive function and understanding of its molecular
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FMR2, had a CCG repeat at its 58 end associated with
FRAXE. Expansion of FRAXE CCG repeats beyond a
threshold that resulted in CpG methylation of this re-
gion was shown to silence FMR2 transcription (Ge´cz et
al. 1996, 1997b). The other, IL1RAPL, was interrupted
by a deletion in family MRX34 and then confirmed as
the specific gene affecting cognitive function by detec-
tion of a nonsense mutation in a second MRX family
(Carrie et al. 1999). Another two genes were identified
by positional cloning of the gene at the X breakpoint
of X; autosome translocations in mentally impaired
females. Oligophrenin 1 (OPHN1; Billuart et al. 1998)
and tetraspanin 2 (TM4SF2; Zemni et al. 2000) then
became instant candidates for familial XLMR, and they
were independently confirmed as genes for XLMR by
detection of mutations in families linked to the same
regions. The three remaining genes, GDI1 (D’Adamo et
al. 1998), PAK3 (Allen et al. 1998), and RPS6KA3 (Meri-
enne et al. 1999), were identified by the positional can-
didate approach. Genes within minimal intervals de-
termined from linkage mapping in MRX families are
chosen as candidates to be screened for mutation in
relevant families based on criteria like expression in
brain, tentative involvement in signalling pathways
(see below), or similarity to a known MRX gene. Once
a mutation within a given gene is identified in one
MRX family, other MRX families from the region are
screened to determine the frequency of that gene as a
cause of MRX in MRX families mapping to the same
regions (Fig. 1).
How Many Genes for MR?
Early delineation of the number of MRX genes on the
basis of nonoverlapping localizations led to the mini-
mum estimate of eight (Gedeon et al. 1996). This has
now been increased to 11, with 7 identified MRX genes
plus 4 nonoverlapping regional localizations deter-
mined by linkage that do not yet overlap identified
MRX genes (Fig. 2). Because not all MRX families have
mutations within known MRX genes localizing to the
same interval, the minimum number of different MRX
genes can be conservatively estimated at 22, by merely
doubling the genes in each interval defined so far.
Morton et al. (1977, 1978) predicted at least 325
autosomal genes and at least 17 X-linked genes causing
nonspecific MR based on a mutation rate of 0.008 per
gamete or <2.4 2 1015 per locus. This estimate was
later argued, especially regarding the number of X-
linked genes and, in particular, those implicated in
MRX (Turner and Partington 1991; Morton 1992;
Turner 1996). Empirical estimates of the minimum
number of loci (Fig. 2) are similar to Morton’s original
prediction of at least 17 (but maximum 25) genes for
MRX. Given that only a small proportion of MRX fami-
lies (12% or 9 of ~ 75 reported; Table 1) have been iden-
tified with a mutation in one of the seven presently
characterized MRX genes (see below), the overall num-
ber of X-linked genes implicated in cognitive functions
may be substantially greater than that indicated in Fig-
ure 2. Additionally, there are at least two genes identi-
fied so far from X-chromosome rearrangement break-
points, associated with MRX, that have not yet been
found mutated in MRX families (van der Maarel et al.
1996; Ge´cz et al. 2000); however, involvement of the
autosomal breakpoint has not been excluded in these
cases. Based on these data and numerous documented
cases of X-chromosome rearrangements with unique
breakpoints, all associated with MR, we may speculate
that the number of MRX genes may easily exceed 100.
Figure 2 Ideogram of the X chromosome showing the position
of the seven known MRX genes, two candidate MRX genes [iso-
lated from X; autosome translocation breakpoints, indicated by
an asterisk(*)], and four additional nonoverlapping intervals
shown by corresponding MRX family linkage intervals. These
data indicate that a minimum number of 11 (or 12 when includ-
ing the candidate MRX gene DXS6673E) MRX loci exist on the X
chromosome. Given the fact that only single families from a par-
ticular interval were found to have a mutation in any one of the
currently identified MRX genes, the minimal number of MRX
genes will at least double, that is, reach 22. The MRX numbers
under and above the arrows indicate the individual MRX families
with mutations in that particular MRX gene (e.g., MRX19 for
RPS6KA3). The vertical bars show minimal linkage intervals of
corresponding MRX families with flanking DXS markers indi-
cated.
X-linked Genes for Cognitive Function
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New research approaches will need to be developed to
achieve complete identification of X-chromosome
genes for cognitive function (see below).
Are there any autosomal genes causing only MR?
Surely there are; however, no autosomal nonspecific
MR genes have been identified as yet. Developments
toward identification of these genes lag well behind
developments on the X chromosome that have been
enhanced by the relative ease of expression of X-linked
recessive disorders. Current research into the identifi-
cation of autosomal genes is focused on screening pa-
tients with idiopathic MR for submicroscopic rear-
rangements and deletions particularly in telomeric re-
gions. Several such rearrangements have recently been
identified (Flint et al. 1995; Slavotinek et al. 1999;
Wirth et al. 1999). An approach not yet exploited
would be the ascertainment of families with autosomal
nonspecific MR from populations in which consan-
guinity is practiced, because only in such families will
it be possible to map by linkage the autosomal reces-
sive gene responsible for MR in single sibships. Auto-
somal dominant pedigrees with MR do not appear to
exist, because except for milder forms, this would be
reproductively lethal, and no dominant ones are
known from the X chromosome (where skewed X in-
activation has been excluded). Identification of corre-
sponding autosomal genes for aspects of cognitive
function will build on knowledge accumulating in the
field of X-linked MR, with X-linked and autosomal loci
likely to be coded for proteins in the same molecular
pathways. If the number of MRX genes exceeds 100 (or
even 22) and if genes essential for normal cognitive
function are randomly distributed, then the level of
complexity of the underlying molecular basis for cog-
nitive inability will be enormous.
Genes Identified and Molecular Pathways Involved
Currently, there are seven genes identified with muta-
tions in MRX families and two genes isolated from X;
autosome translocation breakpoints associated with
nonspecific mental impairment (Fig. 2; Table 1): FMR2
(Ge´cz et al. 1996; Gu et al. 1996), GDI1 (D’Adamo et al.
1998); OPHN1 (Billuart et al. 1998), PAK3 (Allen et al.
1998), RPS6KA3 (Merienne et al. 1999), IL1RAPL (Car-
rie et al. 1999), TM4SF2 (Zemni et al. 2000), DXS6673E,
(van der Maarel et al. 1996), and GRIA3 (Ge´cz et al.
2000). It is intriguing that six of these seven genes
(GDI1, OPHN1, PAK3, RPS6KA3, IL1RAPL, and TM4SF2)
have been shown to participate in various stages of
intracellular signaling (Antonarakis and Van Aelst
1998; Chelly 1999). GDI1 and oligophrenin 1 regu-
late Rab and Rho GTPases involved in vesicle cycling,
neurotransmitter release, cell migration, and neurite
outgrowth (Van Aelst and D’Souza-Schorey 1997).
PAK3 is one of the downstream effectors of Rho
GTPases (Rac and Cdc42) carrying the signal to the
actin cytoskeleton (Sells et al. 1997) and MAP ki-
nase cascades including c-Jun amino-terminal kinase 1
(JNK1) and p38 (Bagrodia et al. 1995). Interestingly,
one of the other recently identified MRX genes,
IL1RAPL (Carrie et al. 1999) participates in the inter-
leukin (IL-1) signaling pathway that involves activa-
tion of JNK kinase as well (Bagrodia et al. 1995).
RPS6KA3 with some residual activity is associated with
MRX after being characterized previously for more se-
vere mutations associated with Coffin-Lowry syn-
drome (CLS; Trivier et al. 1996). It is a MAPK activated
CREB kinase with important cellular function in regu-
lation of immediate-early gene transcription (Xing et
al. 1996). TM4SF2, or tetraspanin-2, is an integrin-
associated protein that can modulate integrin signal-
Table 1. Cloned MRX Genes
Year MRX gene Function MRX mutation(s) Reference




Gecz et al. (1996)
Gu et al. (1996)
Gedeon et al. (1995)
1998 GDI1 Rab GDP-dissociation inhibitor MRX41; MRX48;
MRX R
D’Adamo et al. (1998)
Bienvenu et al. (1998)
1998 OPHN1 Rho-GTPase activating protein MRX60; t(X;12) Billuart et al. (1998)
1998 PAK3 p21 activated kinase MRX30
MRX47
Allen et al. (1998)
Chelly (1999)
1999 RPS6KA3 a growth factor regulated kinase MRX19 Merienne et al. (1999)
1999 IL1RAPL interleukin receptor accessory
protein-like
MRX; deletions Carrie et al. (1999)
1999 TM4SF2 integrin associated protein MRX Zemni et al. (2000)
1996 DXS6673E b unknown t(X;13) van der Maarel et al. (2000)
1999 GRIA3 b glutamate receptor AMPA type t(X;12) Gecz et al. (2000)
aThe only gene so far found to be involved in both syndromal (Coffin-Lowry syndrome) and nonspecific (MRX19) XLMRs.
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ing and thus participate in regulation of cell motility
(Berditchevski and Odintsova 1999) and especially
neurite outgrowth (Hemler 1998).
The function of FMR2 (the FRAXE fragile site asso-
ciated gene) is yet to be deciphered. There is some evi-
dence that FMR2 is a nuclear protein with potential to
regulate (activate) transcription (Ge´cz et al. 1997a) and
thus eventually serve as a possible downstream effector
of MAP kinase pathways the other MRX genes are part
of. Preliminary studies on fmr2 knockout mice indicate
no phenotypic or pathologic abnormalities; however,
behavioural studies suggest a defect in tests of condi-
tioned fear (Nelson et al. 1999).
Of the two other candidate MRX genes isolated
from X-chromosome breakpoints but not yet found
mutated in families (Table 1), the function is not
known for the DXS6673E gene. The other, GRIA3, an
AMPA type glutamate receptor is yet another major
player in postsynaptic signaling via Ca2+/calmodulin
(CaM) dependant pathway. The crucial role of gluta-
mate receptors in learning and memory has been
widely supported (Ozawa et al. 1998). Recent findings
on transgenic mice overexpressing a subtype of an
NMDA glutamate receptor gene NR2B in adult brain
that triggered enhanced memory and improved learn-
ing further accentuate the role of glutamate receptor
mediated pathways in cognitive functions (Tang et al.
1999). In addition to NMDA and metabotropic gluta-
mate receptors, the participation of AMPA class gluta-
mate receptors (of which the GRIA3 gene is a member)
in long term potentiation (LTP), a mechanism holding
the key to understanding how memories are formed,
has now been demonstrated (Shi et al. 1999).
The significance of these cellular signaling path-
ways for learning and memory is now unfolding. Mu-
tations in members of the cascade are being identified,
and their functional consequence studied and corre-
lated with the MR phenotype observed in families with
MRX. It appears that most if not all of the MRX genes
show prominent expression in the hippocampus. This
relatively small structure of the brain has long been
considered (Olton et al. 1986) and is presently accepted
(Bliss and Collingridge 1993) as the prime region in-
volved in processes of learning and memory. No varia-
tions in X-linked genes have been identified that
might account for higher IQ (>130), but such families
have not been sought or investigated as the vast ma-
jority of mutations drastically affecting function are
likely to lower IQ.
Future Directions
The genetic complexity underlying cognitive function
seems to be enormous. The molecular tools and tech-
niques will need to be improved and new approaches
developed to move from detection of only genes affect-
ing the extreme phenotype for cognitive function (e.g.,
MRX) to definition of components that modulate fine
tuning of cognitive function within the major range
of variation. FRAXE MR illustrates the problem in-
volved. Several studies now demonstrate that not all
affected individuals (with FRAXE CCG expansion
and subsequent silencing of FMR2 gene transcription),
often brothers, are concordant for reduction of IQ be-
low 70. Expression of FMR2 in these cases is assumed
to be extinguished in the brain, an extrapolation from
results of experiments performed on fibroblasts of
the same patient (Ge´cz et al. 1997b). Had there not
been the unstable (CCG)n marker within the FMR2
gene, the association between FMR2 and MR may
not have been recognized. This clearly points to other
molecular variation (autosomal and/or X-linked)
with similar effects on phenotype (IQ) that would be
even more difficult to recognize by simple family study
than the mild mental impairment associated with
FRAXE.
It is a challenge for the future to decipher the com-
plexity underlying human cognitive function. New
technologies of large scale expression analysis [SAGE
(serial analysis of gene expression), cDNA microarrays,
RNA differential display] and associated informatics
(Somogyi 1999; Zhang 1999) to organize and analyze
these experimental data into meaningful patterns/
pathways might be applied to realize the ultimate goal
of determination of all MR genes (X-linked and auto-
somal). Only then will the beginning of understanding
of function in global terms be achievable. We may en-
visage that based on the growing understanding of X-
linked MR pathology in the not too distant future the
forward genetics approaches (search for interacting
proteins, interconnected pathways; for review, see
Stark and Gudkov 1999) will start to play an increas-
ingly important role in MR gene identification and
characterization. Moreover, preliminary studies on
transgenic mouse models (such as that of the fmr2
mouse) are encouraging and demonstrate the use of
animal transgenics in the understanding of principles
and mechanisms of human learning and memory. The
intriguing question of what makes us different from
our closest mammal and especially primate relatives,
the quality (new function) or the quantity (new genes),
or both, resurfaces. So far all MRX genes currently iden-
tified have homologs in lower species. As to whether
they show the same properties across species remains
to be investigated.
We may speculate that to keep a complex organ
such as the human brain functioning normally re-
quires not one, not two, but hundreds or thousands of
genes integrated in such a way that their products
function in concert. These complex interactions re-
main well balanced even under a variety of environ-
mental stimuli. In contrast, malfunction of only a
single gene may catastrophically disrupt the balance,
X-linked Genes for Cognitive Function
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the lesson learned as genes for MRX are now being
discovered.
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